MetaCap

BridgeBio Oncology Therapeutics Inc. Company Profile

NASDAQ: BBOTHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.81-0.05 (-2.69%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

BridgeBio Oncology Therapeutics at a glance

BridgeBio Oncology Therapeutics Inc. (NASDAQ: BBOT) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in South San Francisco, CA. BridgeBio Oncology Therapeutics is led by Dr. Pedro J. Beltran M.D., Ph.D. and employs about 92 people. The company's shares have traded publicly since 2024.

At a market capitalization of $145.3 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001869105, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does BridgeBio Oncology Therapeutics do?

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.

Business description based on the company's public filings.

Company information

Legal name
BridgeBio Oncology Therapeutics Inc.
Ticker
NASDAQ: BBOT
Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Pedro J. Beltran M.D., Ph.D.
Employees
92
Headquarters
256 East Grand Avenue, South San Francisco, CA, United States
Phone
650 405 4770
Website
bbotx.com
IPO year
2024
Market cap
$145.25M
SEC CIK
0001869105
Latest annual report
10-K · Mar 5, 2026

Companies similar to BridgeBio Oncology Therapeutics

BBOT peer companies
CompanyPrice% ChgMarket capCompare
PRQRProQR Therapeutics N.V.1.04-0.95%$146.98Mvs BBOT
VRXAVeraxa Biotech AG1.04+0.97%$147.06Mvs BBOT
RNAAtrium Therapeutics Inc.6.92-0.86%$149.27Mvs BBOT
ELDNEledon Pharmaceuticals Inc.1.78-6.32%$150.34Mvs BBOT
IFRXInflaRx N.V.1.04-4.59%$153.26Mvs BBOT
ALXOALX Oncology Holdings Inc.1.06+3.92%$137.03Mvs BBOT
ORMPOramed Pharmaceuticals Inc.3.57-3.25%$155.24Mvs BBOT
ZNTLZentalis Pharmaceuticals Inc.1.360.00%$133.64Mvs BBOT

Related